Commercial PA Criteria

Effective: May, 2017

Prior Authorization: Ingrezza

Products Affected: Ingrezza (valbenazine) capsules, Ingrezza (valbenazine) sprinkle capsules

Medication Description:

Ingrezza (valbenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia (TD). The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.

Covered Uses:

1. Treatment of adults with tardive dyskinesia
2. Chorea associated with Huntington's disease.

Exclusion Criteria:

1. Patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval
2. Patients with a hypersensitivity to Ingrezza (valbenazine) or any component of its formulation

Required Medical Information:

1. Dose and frequency
2. Medication history

Age Restrictions: 18 years of age or older

Prescriber Restrictions: Prescribed by or in consultation with a neurologist or psychiatrist.

Coverage Duration: 12 months

Other Criteria:

1. **Chorea Associated with Huntington's Disease**
   Approve if the patient meets the following criteria:
   A. Patient is ≥ 18 years of age; **AND**
   B. Diagnosis of Huntington's disease is confirmed by genetic testing (for example, an expanded HTT CAG repeat sequence of at least 36); **AND**
   C. The medication is prescribed by or in consultation with a neurologist.

2. **Tardive Dyskinesia.**
   Approve if the patient meets the following criteria:
   A. Patient is 18 years of age or older; **AND**
   B. Patient has a diagnosis of tardive dyskinesia; **AND**
   C. The medication is prescribed by or in consultation with a neurologist or psychiatrist.

References:

1. Ingrezza [package insert]. San Diego, CA; Neurocrine Biosciences; April 2017.
2. Hauser RA, Factor SA, Marder SR, et al. KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trail of valbenazine for tardive dyskinesis. Am J Psych. 2017; 174(5): 476-484. DOI: 10.1176/appi.ajp.2017.16091037
3. National Guideline Clearinghouse (NGC). Guideline summary: Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality. Available at: https://www.guideline.gov/summaries/summary/47021/evidencebased-guideline-treatment-of-tardive-syndromes-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	8/16/17
2	Update	Added criteria regarding dose reduction, tapering, or discontinuation of the offending medication	Other Criteria	8/1/2019
3	Update	Removal under tardive dyskinesia i. Patient has persistent symptoms of tardive dyskinesia despite a trial of dose reduction, tapering, or discontinuation of the offending medication OR ii. Patient is not a candidate for a trial of dose reduction, tapering, or discontinuation of the offending medication. Removal of Patient has a history of current or former chronic use of an antipsychotic or other dopamine antagonist Addition of capsules/sprinkle capsule Addition of Chorea associated with Huntington's Disease for approved indications and criteria.	Other criteria Products affected Covered uses	5/21/2024